| Literature DB >> 25717269 |
Abstract
It is known that immunotherapy and cancer chemotherapy may cause hepatitis B virus (HBV) reactivation in hepatitis B surface antigen carriers and inactive chronic hepatitis B patients. Guidelines recommend antiviral prophylaxis regardless of HBV DNA levels to prevent reactivation. We read from the article written by Liu et al that Lamivudine was given inadequate time for antiviral prophylaxis.Entities:
Keywords: Antiviral prophylaxis; Hepatitis B; Hepatitis B reactivation; Immunotherapy; Inadequate time; Lamivudine
Mesh:
Substances:
Year: 2015 PMID: 25717269 PMCID: PMC4326171 DOI: 10.3748/wjg.v21.i7.2263
Source DB: PubMed Journal: World J Gastroenterol ISSN: 1007-9327 Impact factor: 5.742